GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Wells Fargo Healthcare Conference in Boston, MA Friday, September 5, 2025 One-on-one meetings only H.C. Wainwright Global Investment Conference in New York, NY Tuesday, Sept ...

Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disord ...

Financial Performance - Altimmune, Inc. reported a quarterly loss of 27 cents per share, which was better than market estimates of a loss of 32 cents per share [1] - The company's quarterly sales amounted to $5.000K [1] Clinical Development - Pemvidutide showed rapid and robust MASH effects, significant weight loss, and impressive safety and tolerability in the recent IMPACT Phase 2b trial [2] - The company is preparing for an End-of-Phase 2 Meeting with the FDA, which will facilitate the transition to Phase 3 development [2] - Full 48-week data is expected to be reported in the fourth quarter, with further updates anticipated as pemvidutide advances [2] Stock Performance and Analyst Ratings - Following the earnings announcement, Altimmune shares increased by 5.7%, trading at $3.8250 [2] - B. Riley Securities analyst Mayank Mamtani maintained a Buy rating but lowered the price target from $20 to $18 [5] - UBS analyst Eliana Merle also maintained a Buy rating, reducing the price target from $26 to $24 [5] - HC Wainwright & Co. analyst Patrick Trucchio reiterated a Buy rating with a maintained price target of $12 [5]

Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare, Ph.D., to remain on the Board as Independent Director GAITHERSBURG, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that its Board of Directors has appointed Jerry Durso as Chairman, effectiv ...

Core Viewpoint - Investors are expected to focus on Altimmune's progress with its lead pipeline candidate, pemvidutide, during the second-quarter 2025 results announcement, as the company currently lacks a marketed drug and is projected to report a loss of 32 cents per share [1][10]. Group 1: Pipeline Candidate and Clinical Trials - Pemvidutide is a novel, peptide-based GLP-1/glucagon dual receptor agonist being developed for obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease (ALD), and alcohol use disorder (AUD) [2]. - The phase IIb IMPACT study showed that at 24 weeks, 59.1% and 52.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg achieved MASH resolution without worsening fibrosis, compared to 19.1% with placebo [3]. - Fibrosis improvement without worsening MASH was observed in 31.8% and 34.5% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% with placebo, although these differences were not statistically significant [4]. Group 2: Weight Loss and Safety Profile - Participants receiving pemvidutide experienced an average weight loss of 5% with the 1.2 mg dose and 6.2% with the 1.8 mg dose, compared to 1% in the placebo group at 24 weeks, indicating a favorable weight loss profile [5]. - Treatment with pemvidutide was generally safe and well-tolerated, which is a positive aspect for its future development [5]. Group 3: Market Performance and Future Expectations - Year to date, Altimmune's shares have declined by 43%, contrasting with a 7.2% increase in the industry [5]. - The company has initiated two separate phase II studies for pemvidutide targeting AUD and ALD, with further updates expected during the upcoming earnings call [6][7]. - Operating expenses are anticipated to have decreased in the upcoming quarter due to the timing of clinical study costs [7]. Group 4: Earnings Surprise History - Altimmune has a mixed earnings surprise history, having beaten estimates in three of the last four quarters, with an average surprise of 9.21% [8]. - In the last reported quarter, the company posted an earnings surprise of 25.71% [8].

Group 1: Methode Electronics - Methode Electronics reported a fourth-quarter adjusted EPS loss of 77 cents per share, missing market estimates of earnings of 4 cents per share [1] - The company's sales were $257.10 million, exceeding estimates of $232.87 million [1] - Shares of Methode Electronics fell sharply in pre-market trading following the earnings report [1] Group 2: Other Stocks - Mereo BioPharma Group plc shares tumbled 36.6% to $1.87 in pre-market trading [4] - Ultragenyx Pharmaceutical Inc. shares dipped 21.3% to $32.50 in pre-market trading [4] - Wolfspeed, Inc. shares fell 11% to $1.79 in pre-market trading after a 20% drop on Wednesday [4] - Scage Future shares fell 10.5% to $5.89 in pre-market trading after a significant gain of over 56% on Wednesday [4] - Altimmune, Inc. shares dipped 8.4% to $4.34 in pre-market trading following the initiation of a Phase 2 trial [4] - Bitmine Immersion Technologies, Inc. shares fell 7.7% to $61.60 in pre-market trading after a 40% drop on Wednesday due to a mixed shelf filing [4] - Hotel101 Global Holdings Corp. shares dipped 5.3% to $3.42 in after-hours trading [4] - Metsera, Inc. shares fell 4.3% to $33.80 in pre-market trading after a 17% gain on Wednesday [4]

Core Insights - Altimmune, Inc. has initiated the RESTORE Phase 2 trial for pemvidutide, targeting Alcohol-Associated Liver Disease (ALD) [1][2] - Pemvidutide is a dual receptor agonist aimed at treating various liver and cardiometabolic diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Alcohol Use Disorder (AUD) [1][4] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [5] - The lead program, pemvidutide, is designed to address MASH, AUD, ALD, and obesity [5] Clinical Trial Details - The RESTORE trial will enroll approximately 100 patients across 34 sites, with a 1:1 randomization to receive either 2.4mg pemvidutide or placebo for 48 weeks [2] - The primary endpoint is the change in liver stiffness measurement (LSM) at Week 24, with key secondary endpoints including changes in LSM at Week 48 and alcohol consumption [2] Pemvidutide Efficacy - Previous trials, including the IMPACT Phase 2b trial, demonstrated significant reductions in liver fat, body weight, and liver stiffness, supporting the potential efficacy of pemvidutide [3][4] - Pemvidutide has shown class-leading tolerability with low rates of discontinuation due to adverse events [4] Market Need - There are currently no approved treatments for ALD, and over 6 million Americans with Alcohol Use Disorder have progressed to this condition, highlighting the urgent need for effective therapies [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Altimmune, Inc. and its officers or directors following the release of trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Altimmune, Inc. is a publicly traded company on NASDAQ under the ticker symbol ALT [1]. - The company recently announced "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)" [3]. Group 2: Trial Results - The trial results were described as "positive," but the key efficacy endpoint showed fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with differences not being statistically significant [3]. - Following the announcement of these results, Altimmune's stock price fell by $4.10 per share, representing a decline of 53.18%, closing at $3.61 per share on June 26, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors regarding potential securities fraud or other unlawful practices by Altimmune and its management [1]. - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud [4].

Core Viewpoint - Altimmune, Inc. is under investigation for potential securities fraud following the release of mixed results from a clinical trial, which led to a significant drop in its stock price [1][2]. Group 1: Investigation and Legal Context - Pomerantz LLP is investigating claims on behalf of investors of Altimmune regarding possible securities fraud or unlawful business practices by the company and its officers or directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3]. Group 2: Clinical Trial Results and Market Reaction - On June 26, 2025, Altimmune announced "topline results" from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), describing the results as "positive" [2]. - The trial reported fibrosis improvement rates of 31.8% and 34.5% for pemvidutide doses of 1.2 mg and 1.8 mg, respectively, compared to 25.9% for placebo, with the differences not being statistically significant [2]. - Following the announcement, Altimmune's stock price fell by $4.10, or 53.18%, closing at $3.61 per share on the same day [2].

Core Insights - Altimmune, Inc. released topline results from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease [1] Group 1: Trial Details - The Phase 2b trial included 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3, randomized to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses, or placebo for 24 weeks [2] - Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment [3] Group 2: Efficacy Results - In an intent-to-treat (ITT) analysis, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% for pemvidutide 1.2 mg, 52.1% for 1.8 mg, and 19.1% for placebo (p< 0.0001 for both doses) [3] - The effects on fibrosis improvement without worsening of MASH were 31.8% for pemvidutide 1.2 mg, 34.5% for 1.8 mg, compared to 25.9% for placebo, although these differences were not statistically significant [4] Group 3: Analyst Ratings - HC Wainwright reiterated a Buy rating for Altimmune with a price forecast of $12, believing the data supports advancing pemvidutide to Phase 3 and strengthens its case as a potential best-in-class therapy [5] - Conversely, William Blair maintained a Market Perform rating, citing "underwhelming" results and concerns about demonstrating significant fibrosis improvement at the 48-week mark [6] Group 4: Stock Performance - ALT stock is trading lower by 1.80% to $3.545 at last check [7]